Harrison Stafford

This team has the best stable of running backs since the Wishbone days in the late 60’s and early 70’s with Chris Gilbert, Steve Worster, Ted Koy, Jim Bertelsen, Billy Dale, Bobby Callison, Terry Collins, and Paul Robichau

Deal with it Dodgers.

This morning, GERN’s Rytelo has been established the as standard of care in transfusion-dependent myelodysplastic syndrome by the National Comprehensive Cancer Network (NCCN). NCCN sets the standard of care for various cancers. Hence, the bump in today’s GERN sp.

It’s a good thing we didn’t play North Sudan.

No, haven’t had a position in ALT for several years. It ran to $30 in 2020 or 2021 and I sold it around $18 on the way down for a triple. As far as buyout candidates go, I like GERN. They had a blood cancer drug approved by the FDA in June and are direct competitors to both Merck and Bristol-Myers Squibb. My guess is the buyout happens in 9 months to a year.

About a month and a half into my first year at UT, my mom called me, said she was changing my bedroom into a guest bedroom, and if there was anything in my room I wanted to keep, I’d best come home that weekend to claim it. Sooo, I was able to get some clothes, my electric football game, and my baseball cards. Since we’re at the All Star break, I thought this might be a good time to share some of those cards from Houston’s MLB franchise.

And only if he’s sitting in the nosebleeds.

EOSE with another up day. +.19 to $2.31.

EOSE +.06 to $2.12. GERN +.16 to $4.76. Good day.

https://www.eenews.net/articles/biden-signs-a-big-nuclear-bill-can-it-remake-the-industry Why UUUU is up today.

AMYZF is now revenue producing with more to come. Ditto on the $10. I have 125,000 shares and when it hits that sp, I’ll rent a party room in Austin and drinks are on me.

https://www.otcmarkets.com/stock/AMYZF/news/RecycLiCo-Taiwan-Battery-Recycling-Joint-Venture-Commences-Production-and-Sales-of-Black-Powder?id=446104 Why AMYZF is positive for the day.

Will sell half the position at $10 and let the other half ride.

I’d take a position in both IBRX and GERN. Both are biotechs and both have had cancer drugs recently approved by the FDA. IBRX’s Anktiva was approved on April 22 for the treatment of bladder cancer and IBRX began shipping Anktiva two weeks after approval. These sales should be reflected in IBRX’s Q2 earnings. As more and more healthcare plans allow for Anktiva reimbursement, earnings should continue to grow in each successive quarter for the foreseeable future as Anktiva becomes the standard of care for the treatment of bladder cancer. But, that’s just the start of the story. IBRX, per their website, met with the FDA in June to get the green light to use Anktiva for the treatment of 2nd line and 3rd line lung cancer. As Anktiva is already an approved drug for bladder cancer, label expansion is not usually as difficult as a new set of trials. IBRX also has ongoing trials using Anktiva in conjunction with other drugs/vaccines to treat colorectal cancer, ovarian cancer, pancreatic cancer, glioblastoma, and leukemia and all these are in phase 2 trials. There’s also phase 1 trials for HPV, advanced solid tumors, non-Hodgkin lymphoma, and HIV also marrying Anktiva with other drugs/vaccines as treatment. Go to ImmunityBio’s website Immunitybio.com and read about what this company is doing. GERN’s drug, Rytelo (formerly Imetelstat), was approved on June 6 and is used for treating transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes (MDS), a group of blood cancers. I think GERN is a big time takeover target and (if there’s a buyout) goes at 4x the current sp. Maybe more. If Big Pharma won’t pony up the big $$ to buy GERN, I still expect the sp to go much higher as Rytelo sales start to come in and the drug is approved in additional indications (mainly MF and AML). Buyout or no buyout, you should make money…unless something comes out of left field that is completely unforeseen.

We have a team that, potentially, can compete for the WS and we have a coach that’s a rookie.

EOSE +.20 to $1.97. Volume today is already almost twice that of avg. daily volume.

We don’t want any candy stripes on our uniforms. These are work clothes.” — Darrell Royal

*aggys

Living in a Van Down By The River?

Oooooooh, I like.